Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;19(1):86-93.
doi: 10.1007/s11904-021-00597-4. Epub 2022 Jan 28.

HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development

Brittany Ober Shepherd  1   2 , David Chang  3 , Sandhya Vasan  1   2   3 , Julie Ake  2 , Kayvon Modjarrad  4
Affiliations
Review

HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development

Brittany Ober Shepherd et al. Curr HIV/AIDS Rep. 2022 Feb.

Abstract

Purpose of review: This review examines the major advances and obstacles in the field of HIV vaccine research as they pertain to informing the development of vaccines against SARS-CoV-2.

Recent findings: Although the field of HIV research has yet to deliver a licensed vaccine, the technologies developed and knowledge gained in basic scientific disciplines, translational research, and community engagement have positively impacted the development of vaccines for other viruses, most notably and recently for SARS-CoV-2. These advances include the advent of viral vectors and mRNA as vaccine delivery platforms; the use of structural biology for immunogen design; an emergence of novel adjuvant formulations; a more sophisticated understanding of viral phylogenetics; improvements in the development and harmonization of accurate assays for vaccine immunogenicity; and maturation of the fields of bioethics and community engagement for clinical trials conducted in diverse populations. Decades of foundational research and investments into HIV biology, though yet to yield an authorized or approved vaccine for HIV/AIDS, have now paid dividends in the rapid development of safe and effective SARS-CoV-2 vaccines. This latter success presents an opportunity for feedback on improved pathways for development of safe and efficacious vaccines against HIV and other pathogens.

Keywords: HIV; Lessons; Research; SARS-COV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

K. Modjarrad is a principal inventor of the SARS-CoV-2 Spike ferritin nanoparticle (SpFN) vaccine.

References

    1. Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–1468. doi: 10.1126/science.1690918. - DOI - PubMed
    1. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780. doi: 10.1038/nrd4278. - DOI - PubMed
    1. Coughlan L, et al. Heterologous two-dose vaccination with Simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults. EBioMedicine. 2018;29:146–154. doi: 10.1016/j.ebiom.2018.02.011. - DOI - PMC - PubMed
    1. Dicks MD, et al., A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One, 2012. 7(7): e40385. - PMC - PubMed
    1. Barouch DH, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13–19) Lancet. 2018;392(10143):232–243. doi: 10.1016/S0140-6736(18)31364-3. - DOI - PMC - PubMed

LinkOut - more resources